Advertisement

Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma

      Abstract

      Purpose

      To compare fluorine-18 fluorodeoxyglucose positron emission tomography (PET) and gallium scanning with each other and with conventional staging, for patients with Hodgkin’s disease or non-Hodgkin’s lymphoma.

      Subjects and methods

      Fifty patients had PET, gallium scanning, and conventional staging of newly diagnosed or progressive Hodgkin’s disease or non-Hodgkin’s lymphoma. Disease sites, stage, and treatment plans were assessed retrospectively.

      Results

      Positron emission tomography and gallium scanning each upstaged 14% of patients (n = 7). Management was altered by PET in 9 cases (18%) and by gallium scanning in 7 (14%, P = 0.6). Disease was evident in 117 sites in 42 patients. The case positivity rate for conventional assessment was 90%; for PET, 95%; for gallium scanning, 88%; for conventional assessment plus PET, 100%; and for conventional assessment plus gallium scanning, 98%. Site positivity rates for conventional assessment were 68%; for PET, 82%; for gallium scanning, 69% (conventional vs. PET, P = 0.01; conventional vs. gallium scanning, P = 0.9; PET vs. gallium scanning, P = 0.01); for conventional assessment plus PET, 96%; and for conventional assessment plus gallium scanning, 94%. Positron emission tomography and gallium scanning were entirely concordant in 31 patients; in the other 19 patients, PET identified 25 sites missed by gallium scanning, whereas gallium scanning identified 10 sites missed by PET.

      Conclusion

      In this retrospective study, PET demonstrated a higher site positivity rate than did gallium scanning, with similar case positivity rates. These data support the use of PET in place of gallium scanning for the staging of patients with Hodgkin’s disease or non-Hodgkin’s lymphoma.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Canellos G
        Residual mass in lymphoma may not be residual disease.
        J Clin Oncol. 1988; 6: 31-33
        • Smitt M.C
        • Stouffer N
        • Owen J.B
        • et al.
        Results of the 1988–1989 Patterns of Care Study process survey for Hodgkin’s disease.
        Int J Radiat Oncol Bio Phys. 1999; 43: 335-339
        • Morris J
        The stage is set for the diffusion of positron emission tomography in oncology.
        Med J Aust. 1999; 171: 527-528
        • Willkomm P
        • Palmedo H
        • Grunwald F
        • et al.
        Functional imaging of Hodgkin’s disease with FDG-PET and gallium-67.
        Nuklearmedizin. 1998; 37: 251-253
        • Paul R
        Comparison of fluorine-18-2-fluorodeoxyglucose and gallium 67 citrate imaging for detection of lymphoma.
        J Nucl Med. 1987; 28: 288-292
        • Okada J
        • Yoshikawa K
        • Imazeki K
        • et al.
        The use of FDG PET in the detection and management of malignant lymphomas.
        J Nucl Med. 1991; 32: 686-691
        • Karp J
        • Muehllener G
        • Mankoff D
        • et al.
        Continuous slice PENN-PET.
        J Nucl Med. 1990; 31: 617-627
        • Simon R
        • Durrleman S
        • Hoppe R
        • et al.
        The non-Hodgkin’s lymphoma pathologic classification project.
        Ann Intern Med. 1988; 109: 939-945
        • Lister T
        • Crowther D
        • Suttcliffe S
        • et al.
        Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease.
        J Clin Oncol. 1989; 7: 1630-1636
        • Bangerter M
        • Griesshammer M
        • Binder T
        • et al.
        New diagnostic imaging procedures in Hodgkin’s disease.
        Ann Oncol. 1996; 4: 55-59
        • McLaughlin A.F
        • Magee M.A
        • Greenough R
        • et al.
        Current role of gallium scanning in the management of lymphoma.
        Eur J Nucl Med. 1990; 16: 755-771
        • Bartold S.P
        • Donohoe K.J
        • Fletcher J.W
        • et al.
        Procedure guideline for gallium scintigraphy in the evaluation of malignant disease. Society of Nuclear Medicine.
        J Nucl Med. 1997; 38: 990-994
        • Weinblatt M.E
        • Zanzi I
        • Belakhlef A
        • et al.
        False-positive FDG-PET imaging of the thymus of a child with Hodgkin’s disease.
        J Nucl Med. 1997; 38: 888-890
        • Even-Sapir E
        • Bar-Shalom R
        • Israel O
        • et al.
        Single-photon emission computed tomography quantitation of gallium citrate uptake for the differentiation of lymphoma from benign hilar uptake.
        J Clin Oncol. 1995; 13: 942-946
        • Cook G
        • Maisey M
        • Fogelman I
        Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine.
        Eur J Nucl Med. 1999; 26: 1363-1378
        • Stumpe K.D
        • Urbinelli M
        • Steinert H.C
        • et al.
        Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma.
        Eur J Nucl Med. 1998; 25: 721-728
        • Jerusalem G
        • Warland V
        • Najjar F
        • et al.
        Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma.
        Nucl Med Commun. 1999; 20: 13-20
        • Hoh C.K
        • Glaspy J
        • Rosen P
        • et al.
        Whole-body FDG-PET imaging for staging of Hodgkin’s disease and lymphoma.
        J Nucl Med. 1997; 38: 343-348
        • Moog F
        • Bangerter M
        • Diederichs C.G
        • et al.
        Lymphoma.
        Radiology. 1997; 203: 795-800
        • Rodriguez M
        • Rehn S
        • Ahlstrom H
        • et al.
        Predicting malignancy grade with PET in non-Hodgkin’s lymphoma.
        J Nucl Med. 1995; 36: 1790-1796
        • Schonberger J.A
        • Stollfus J.C
        • Kocher F
        Whole-body 18-FDG-PET for staging of malignant lymphomas.
        Eur J Nucl Med. 1994; 21: 727
        • Leskinen-Kallio S
        • Ruotsalainen U
        • Nagren K
        • et al.
        Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin’s lymphoma.
        J Nucl Med. 1991; 32: 1211-1218
        • Newman J.S
        • Francis I.R
        • Kaminski M.S
        • Wahl R.L
        Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.
        Radiology. 1994; 190: 111-116
        • Gallamini A
        • Biggi A
        • Fruttero A
        • et al.
        Revisiting the prognostic role of gallium scintigraphy in low-grade non-Hodgkin’s lymphoma.
        Eur J Nucl Med. 1997; 24: 1499-1506
        • Hussain R
        • Christie D.R
        • Gebski V
        • et al.
        The role of the gallium scan in primary extranodal lymphoma.
        J Nucl Med. 1998; 39: 95-98
        • Ben-Haim S
        • Bar-Shalom R
        • Israel O
        • et al.
        Utility of gallium-67 scintigraphy in low-grade non-Hodgkin’s lymphoma.
        J Clin Oncol. 1996; 14: 1936-1942
        • Moog F
        • Bangerter M
        • Diedrichs C.G
        • et al.
        Extranodal malignant lymphoma.
        Radiology. 1998; 206: 475-481
        • Moog F
        • Bangerter M
        • Kotzerke J
        • et al.
        18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
        J Clin Oncol. 1998; 16: 603-609
        • Front D
        • Israel O
        The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients.
        Semin Nucl Med. 1995; 25: 60-71
        • Miller T
        • Dahlberg S
        • Cassady J
        • et al.
        Chemotherapy alone compared with chemotherapy plus radiotherapy for localised intermediate- and high-grade non-Hodgkin’s lymphoma.
        N Engl J Med. 1998; 339: 21-26
        • Seymour J
        • McLaughlin P
        • Fuller L
        • et al.
        High rate of prolonged remissions following combined modality therapy for patients with localised low-grade lymphoma.
        Ann Oncol. 1996; 7: 157-163
        • Wirth A
        • Wolf M
        • Prince H
        Current trends in the management of early stage Hodgkin’s disease.
        Aust N Z J Med. 1999; 29: 535-544
        • Wirth A
        • Chao M
        • Corry J
        • et al.
        Mantle irradiation alone for clinical stage I-II Hodgkin’s disease.
        J Clin Oncol. 1999; 17: 230-240
        • MacManus M
        • Hoppe R
        Is radiotherapy curative for stage I-II low grade follicular lymphoma? Results of long-term follow-up of patients treated at Stanford university.
        J Clin Oncol. 1996; 14: 1282-1290
        • Larcos G
        • Farlow D.C
        • Antico V.F
        • et al.
        The role of high dose 67-gallium scintigraphy in staging untreated patients with lymphoma.
        Aust N Z J Med. 1994; 24: 5-8
        • Jochelson M.S
        • Herman T.S
        • Stomper P.C
        • et al.
        Planning mantle radiation therapy in patients with Hodgkin disease.
        Am J Roentgenol. 1988; 151: 1229-1231
        • Talbot J
        • Haioun C
        • Rain J
        • et al.
        18-FDG positron imaging in clinical management of lymphoma patients.
        Clin Rev Oncol Hematol. 2001; 38: 193-221
        • Klose T
        • Reiner L
        • Buchmann I
        • et al.
        Primary staging of lymphomas.
        Eur J Nucl Med. 2000; 27: 1457-1464
        • Spaepen K
        • Stroobants S
        • Dupont P
        • et al.
        Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG after first-line chemotherapy in non-Hodgkin’s lymphoma.
        J Clin Oncol. 2001; 19: 414-419
        • Front D
        • Bar-Shalom R
        • Israel O
        The continuing clinical role of gallium 67 scintigraphy in the age of receptor imaging.
        Semin Nucl Med. 1997; 27: 68-74